#gene therapy

Gene Therapy

One limitation of in vivo gene therapy is:

Direct in vivo administration viral vectors faces major limitation reduced control which cells internalize vector genome achieve therapeutic expression compared ex vivo selection. Systemic IV infusion distributes AAV particles according cardiac output vascular permeability liver sinusoidal fenestrations 100 nm capturing ~90 percent dose via heparan sulfate proteoglycan uptake hepatocytes Kupffer macrophages while target skeletal myofibers CNS neurons behind blood-brain barrier differentiated airway epithelia receive subtherapeutic copy numbers below threshold efficacy. No selection feasible after injection unlike ex vivo protocols CD34 immunomagnetic sorting isolates progenitors >95 percent purity. Preexisting neutralizing IgG antibodies AAV2 AAV9 natural infection completely neutralize capsids preventing transduction. Promoter leakage driving expression antigen-presenting dendritic cells leads transgene presentation MHC I triggering CTL elimination loss expression months. Dosimetry cannot be titrated after delivery integration site analysis impossible pretreatment. Strategies improving specificity include capsid engineering inserting RGD peptide targeting alphaV integrins transcriptional targeting tissue-specific promoters synapsin for neurons muscle CK for muscle local injection limiting biodistribution increasing safety profile.

Ref: Molecular Therapy In Vivo Targeting Limitations 2021; FDA Guidance In Vivo Gene Therapy Low Control Challenges; Lodish Gene Delivery Biodistribution Barriers Chap 9.

View Details

Gene Therapy

Target cells in cardiovascular gene therapy include:

Endothelial cell central therapeutic target cardiovascular gene therapy because monolayer regulates vascular homeostasis via eNOS converting L-arginine to nitric oxide stimulating soluble guanylate cyclase raising cGMP relaxing smooth muscle, prostacyclin via COX2 inhibiting platelet aggregation, barrier integrity VE-cadherin junctions, leukocyte adhesion E-selectin VCAM1. Dysfunction oxidative stress uncoupling eNOS drives atherosclerosis hypertension ischemia. Ischemic peripheral artery disease refractory angina benefit proangiogenic factors VEGF-A165, FGF4, HGF, HIF1-alpha delivered AAV1 or plasmid catheter-based intracoronary or intramuscular promoting collateral vessel formation endothelial proliferation migration MAPK ERK and PI3K Akt pathways. Heart failure SERCA2a therapy improves cardiomyocyte calcium handling but endothelial transduction improving perfusion upstream essential. Promoters Tie2, VE-cadherin, endothelin enhancer confer specificity limiting off-target expression reducing neointimal hyperplasia after percutaneous coronary intervention. Restoration barrier reduces thrombogenicity and inflammatory infiltration critical for long-term graft patency. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation.

Ref: Circ Res Cardiovascular Gene Therapy Endothelial Targets 2022; NHLBI Vascular Gene Therapy Overview; Lodish Vascular Biology Endothelial Function Chap 22.

View Details

Gene Therapy

Cancer gene therapy often uses strategy of:

Cancer gene therapy predominantly adopts tumoricidal strategy rather than restoration tumor suppressor because cancer genome carries multiple gain-of-function oncogenes KRAS MYC aneuploidy heterogeneity complicating simple addition. Methods eliminate malignant clone through introduction genes triggering death or immune recruitment. Oncolytic adenoviruses engineered deletion E1B 55 kDa protein normally inactivating p53 replicate selectively p53-deficient cancers lysing cells via viral burst releasing PAMPs tumor antigens danger signals ATP calreticulin HMGB1 driving immunogenic cell death. Suicide enzyme systems HSV TK ganciclovir produce toxic dGTP analog inducing apoptosis. Cytokine transgenes GM-CSF IL-12 IFN-alpha secreted transduced tumor cells recruit dendritic cells cytotoxic T lymphocytes cross-presenting released antigens epitope spreading generating systemic immunity targeting distant metastases abscopal effect. CAR-T gene editing deleting TRAC preventing graft-versus-host PDCD1 enhancing persistence exemplifies combined transfer editing enhancing tumoricidal efficacy overcoming resistance inherent monogenic correction approaches limited single gene restoration. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation.

Ref: Nature Reviews Cancer Gene Therapy Oncolytic Mechanisms 2021; NCI Cancer Gene Therapy Targeted Killing; Molecular Therapy Oncolytic Viruses 2021.

View Details

Gene Therapy

Hemophilia gene therapy targets deficiency of:

Hemophilia A 1 in 5000 males and B 1 in 30000 males result null mutations coagulation cofactors FVIII 280 kDa glycoprotein encoded F8 Xq28 domains A1 A2 B A3 C1 C2 and FIX vitamin K dependent serine protease encoded F9 Xq27 gamma carboxyglutamic acid residues binding calcium phospholipid. Both assemble intrinsic tenase complex FVIIIa cofactor enhancing FIXa protease activity 200000-fold toward FX activation on phosphatidylserine-rich platelet surface accelerating thrombin burst fibrin clot formation. Deficiency prolongs aPTT causing hemarthrosis, muscle hematoma. Replacement requires frequent IV infusions half-life FVIII 12h FIX 18h. Gene therapy delivers codon-optimized B-domain-deleted F8 central 908 aa dispensable removed reducing size 4.4 kb fitting AAV, or FIX Padua variant R338L leucine substitution arginine 338 increasing specific activity 8-fold improving secretion. Hepatotropic AAV5 AAV6 liver-specific promoter HLP transcribe hepatocytes synthesize factor secreting into sinusoids restoring plasma levels 5-150 percent converting severe to mild reducing annualized bleeding rate 90 percent in trials Hemgenix Roctavian leading to regulatory approvals.

Ref: NEJM Hemophilia Gene Therapy Nathwani 2022; FDA Hemgenix Roctavian Approvals; Alberts Cell Biology Coagulation Cascade Chap 20.

View Details

Gene Therapy

Which disease was among the first targets of gene therapy?

Adenosine deaminase deficiency autosomal recessive SCID became earliest successful gene therapy target due biological features favoring correction. Enzyme chromosome 20q13.12 deaminates adenosine to inosine and deoxyadenosine to deoxyinosine, deficiency leads accumulation deoxyadenosine converted deoxycytidine kinase to dATP elevated dATP allosterically inhibits ribonucleotide reductase essential dNTP synthesis DNA replication lymphocyte clonal expansion triggers apoptosis intrinsic pathway resulting absent T B NK cells. Lymphoid lineage provides selective advantage because corrected cells detoxify metabolite locally via metabolic cross-correction proliferate growth advantage while uncorrected die amplifying gene-marked population without myeloablation similar natural reversion mosaicism. HSC accessible bone marrow aspiration amenable retroviral transduction MoMLV vector carrying ADA cDNA under LTR promoter. First trial 1990 Anderson Blaese Rosenberg infused autologous transduced T lymphocytes demonstrating persistence partial enzyme activity. Later Strimvelis product autologous CD34 cells gamma retroviral vector achieved immune reconstitution and became first ex vivo gene therapy approved Europe highlighting importance long-term monitoring leukemia due insertional activation.

Ref: Lancet ADA First Gene Therapy NEJM 1990; NCBI SCID Gene Therapy History; NCERT Biotechnology Applications ADA Chapter 12.

View Details

Gene Therapy

CRISPR, ZFN and TALEN are used in gene therapy for:

CRISPR-Cas9, ZFN, TALEN constitute programmable site-specific endonucleases enabling precise genome manipulation. CRISPR uses single-guide RNA 20 nt spacer complementary to genomic target adjacent NGG PAM recognized Streptococcus pyogenes Cas9 possessing HNH domain cleaving complementary strand RuvC noncomplementary generating blunt double-strand break 3 bp upstream PAM. Zinc-finger arrays modules each recognizing 3 bp triplets linked FokI nuclease dimerize cutting within spacer, while TALEN repeats repeat-variable di-residues HD recognizing cytosine NI adenine NG thymine NN guanine provide single-base flexibility. Cellular repair via error-prone nonhomologous end-joining introduces indels knocking out CCR5 for HIV resistance, while homology-directed repair donor template 400 bp homology arms flanking break precisely corrects sickle HBB glutamate 6 valine mutation or inserts therapeutic transgene into safe harbor AAVS1 chromosome 19 constitutive expression under endogenous promoter. Permanent genomic alteration distinguishes editing from transient augmentation offering curative potential single intervention approved exagamglogene autotemcel for sickle cell. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation.

Ref: NIH Genome Editing CRISPR ZFN TALEN Overview; Nature Biotech Comparison 2020; NCBI Gene Editing Therapy https://www.ncbi.nlm.nih.gov/books/NBK542207/.

View Details

Gene Therapy

Targeted killing of cells in gene therapy often uses:

Targeted killing arms tumor cells with enzymes converting systemically administered non-toxic prodrugs into potent cytotoxins achieving spatial specificity. Classic systems include HSV thymidine kinase type 1 phosphorylating ganciclovir 1000-fold higher affinity than mammalian kinase, E. coli cytosine deaminase codA converting 5-fluorocytosine to 5-fluorouracil inhibiting thymidylate synthase, bacterial nitroreductase NfsB reducing CB1954 to bifunctional alkylating crosslinking DNA. Expression restricted malignant cells using tumor-specific promoters survivin active G2/M, hTERT active 85 percent cancers silent differentiated tissue, CEA for colorectal carcinoma, or hypoxia-responsive elements containing HIF1 binding sites. Vector generally serotype 5 adenovirus injected intratumorally transduces fraction but toxic metabolites diffuse gap junction channels connexin 43 hexamers producing bystander effect killing neighboring nontransduced cells up to 10 diameters amplifying efficacy beyond transduction efficiency. Dividing cells preferentially incorporate nucleotide analogs prompting ATR-CHK1 DNA damage response p53 dependent apoptosis while quiescent normal tissue largely spared synergizing radiotherapy and checkpoint blockade. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation.

Ref: PMC Suicide Gene Therapy HSV-TK Review; Nature Cancer Suicide Systems Overview; Lodish Molecular Biology Prodrug Activation Chap 23.

View Details

Gene Therapy

Gene augmentation therapy (GAT) is used to:

Gene augmentation alias addition therapy provides supplemental functional copy gene compensating recessive loss-of-function mutation where endogenous loci produce truncated or misfolded protein rapidly degraded proteasome or nonsense-mediated decay. Delivered cDNA lacks introns and native regulatory elements codon-optimized enhancing translation and CpG depleted reducing TLR9 activation expressed under heterologous constitutive promoter chicken beta-actin with CMV enhancer or tissue-specific transthyretin promoter driving strong transcription independent defective locus that remains present but inactive. After nuclear entry via nuclear pore, construct episomally or integrally transcribed RNA polymerase II mRNA capping polyadenylation SV40 late signal export NXF1 pathway translation rough ER producing protein folding via BiP disulfide isomerases trafficking Golgi acquiring glycans secreted plasma restoring metabolic pathway such as phenylalanine hydroxylase or clotting factor activity above 5 percent threshold converting severe to mild phenotype. Strategy avoids chromosome editing avoiding double-strand break off-target risks while achieving therapeutic threshold suitable dose control. This mechanistic insight guides vector optimization, dosing strategies, and clinical safety monitoring essential for translational development and regulatory evaluation.

Ref: NIH Gene Augmentation Therapy Strategy; Watson Molecular Biology Gene Augmentation Chap 15; NCBI Bookshelf Gene Addition https://www.ncbi.nlm.nih.gov/books/NBK21981/.

View Details

Gene Therapy

Which method directly delivers naked DNA into cells?

Electroporation applies brief high-intensity electric fields to transiently permeabilize lipid bilayer enabling direct cytosolic entry naked nucleic acids without chemical carriers. Square-wave pulses 100-1500 V/cm for microseconds to tens milliseconds generate transmembrane potential exceeding dielectric strength 0.2-1 V causing rearrangement lipids forming aqueous pores water intrusion between headgroups. Polyanionic DNA driven electrophoretically toward anode migrates through pores reaching cytoplasm within milliseconds before rapid resealing seconds mediated lateral diffusion and calcium-dependent exocytosis. Efficiency depends buffer conductivity, osmolality, cell diameter affecting induced potential proportional radius, pulse number, DNA concentration. Nuclear entry limiting but mitosis or nuclear localization signals improve. In vivo devices needle array electrodes deliver 50-500 V intramuscularly achieving DNA vaccine uptake myofibers and dendritic cells triggering MHC I and II presentation. Ex vivo clinical-scale electroporators transfect primary human T cells CD34 stem cells with mRNA or Cas9 RNP achieving 80 percent efficiency preserving viability avoiding insertional mutagenesis and viral manufacturing complexity suitable repeated applications.

Ref: FDA Guidance Electroporation Devices 2021; Molecular Therapy Methods Electroporation Protocol; NCERT Biotechnology Ch 11 Electroporation Principles.

View Details

Gene Therapy

Non-viral vectors include:

Non-viral delivery uses chemically defined materials condensing nucleic acids avoiding viral capsid immunity and packaging limits. Cationic liposomes DOTAP, DOTMA, helper DOPE facilitating hexagonal phase transition, and cholesterol stabilizing bilayer electrostatically interact with negatively charged phosphate backbone plasmid DNA or mRNA condensing into lipoplexes 100-300 nm diameter positive zeta potential promoting binding anionic proteoglycans initiating endocytosis via clathrin and caveolae. Modern LNPs employ ionizable lipids DLin-MC3-DMA neutral at physiological pH 7.4 minimizing toxicity but cationic upon protonation acidic endosomal lumen pH 5.5-6.0 destabilizing endosomal membrane via inverted hexagonal structure releasing RNA into cytosol for ribosomal translation. Absence viral proteins eliminates insertional mutagenesis permits repeated dosing, scalability via microfluidic mixing, and accommodation large plasmids >10 kb. Transient expression suits vaccination and Cas9 provision where permanent integration undesirable, reducing oncogenesis. Cytotoxicity from cationic lipids at high doses managed by optimization lipid:DNA ratio and inclusion PEG-lipid shielding reducing opsonization and prolonging circulation enabling targeted delivery.

Ref: Lodish Molecular Cell Biology Non-viral Vectors Chap 9; NIH Non-viral Gene Delivery Liposomes Review; Alberts Membrane Fusion Liposome Mechanism.

View Details

Gene Therapy

Which viral vector shows very low immune response?

Recombinant AAV produced by triple transfection HEK293 cells with plasmids encoding rep/cap removed from vector, adenoviral helper functions E2A E4 VA RNA, and vector genome flanked by ITRs yields particles depleted viral coding sequences that normally generate PAMPs triggering innate and adaptive immunity. Capsid proteins VP1 VP2 VP3 ratio 1:1:10 from serotypes AAV2 AAV5 AAV9 exhibit low TLR2 mediated NF-kB activation and minimal TLR9 stimulation due to CpG depletion via codon optimization resulting reduced type I interferons, TNF-alpha, IL-12. Consequently transduced hepatocytes, muscle fibers, dorsal root ganglia display prolonged persistence without CTL elimination although capsid-specific CD8 cells can occur at high doses. Humoral neutralizing antibodies predominantly preexisting limits redosing but allows primary treatment. Episomal concatemers persist as circular monomers multimers associated with histones providing transcriptionally active chromatin for years minimal genotoxicity due low random integration

Ref: PMC AAV Low Immunogenicity Review PMCID 10142300; UQ Biomedical Sciences Vector Immunogenicity Comparison; Nature Med AAV Clinical Safety.

View Details

Gene Therapy

Stable integration into host genome is a feature of:

Lentiviral vectors originating from HIV-1 carry two copies ssRNA genome 9 kb encapsidated with reverse transcriptase, integrase, nucleocapsid. Entry mediated by VSV-G pseudotyping binding LDL receptor ubiquitous, membrane fusion releasing core into cytoplasm where reverse transcriptase synthesizes ds cDNA via tRNA lys3 primer and strand transfer forming preintegration complex containing integrase, matrix p17, Vpr, host LEDGF p75 tethering factor. Complex traverses intact nuclear pore via importin alpha/beta pathway recognizing nuclear localization signals allowing transduction nondividing cells such as neurons and quiescent HSC unlike gamma retroviruses dependent on mitotic envelope breakdown. Integrase catalyzes 3 prime processing removing GT dinucleotides and strand transfer inserting provirus preferentially into active transcription units enriched H3K36 trimethylation marked by LEDGF reader ensuring expression. Self-inactivating design deletes U3 enhancer promoter in LTR abolishing LTR transcriptional activity reducing oncogenic transactivation risk. Integrated provirus replicates with host chromosomes providing stable long-term expression utilized in ex vivo hematopoietic correction and CAR-T manufacturing where durability essential despite low insertional risk.

Ref: Danaher Lentiviral Integration Mechanism; PMC Lentiviral Delivery CRISPR Review; NIH AAV vs Lentivirus Integration Safety.

View Details